FDMT News and Press, 4D Molecular Therapeutics Inc. From 05/08/25

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027 ...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

2025-05-01 10:11:30 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression Cantor analysts call for RFK Jr. replacement following ousting of Marks at FDA How Peter Marks' FDA departure is impacting pharma, biotech st...

EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefit...

EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits t...

2025-04-01 01:03:31 ET More on CRISPR Therapeutics, Moderna FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade) CRISPR Therapeutics Set To Reach Previous Heights Intel And Crispr: 2 'Bond-Like' Option Trades Yielding 13%+ How Peter Marks' F...

2025-03-31 12:37:32 ET More on Beam, CRISPR Therapeutics Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication CRISPR Therapeutics Set To Reach Previous Heights Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene ...

EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits t...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued favorable tolerability Announced positive interim 32-week data for 4D-15...

2025-02-18 14:33:48 ET Summary 4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allo...